China Viral Vector And Plasmid Dna Manufacturing Market Size & Outlook
Related Markets
China viral vector and plasmid dna manufacturing market highlights
- The China viral vector and plasmid dna manufacturing market generated a revenue of USD 319.5 million in 2025 and is expected to reach USD 1,176.0 million by 2033.
- The China market is expected to grow at a CAGR of 18.1% from 2026 to 2033.
- In terms of segment, lentivirus was the largest revenue generating vector type in 2025.
- Adeno-associated virus (AAV) is the most lucrative vector type segment registering the fastest growth during the forecast period.
Viral vector and plasmid dna manufacturing market data book summary
| Market revenue in 2025 | USD 319.5 million |
| Market revenue in 2033 | USD 1,176.0 million |
| Growth rate | 18.1% (CAGR from 2026 to 2033) |
| Largest segment | Lentivirus |
| Fastest growing segment | Adeno-associated virus (AAV) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, Plasmids |
| Key market players worldwide | Merck KGaA, Lonza Group Ltd, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Catalent Inc, WuXi Biologics (Cayman) Inc, Takara Bio Inc, Batavia Biosciences, Miltenyi Biotec, Revvity Inc, BioNTech SE ADR, Astellas Pharma Inc, Biomarin Pharmaceutical Inc, Regenxbio Inc |
Other key industry trends
- In terms of revenue, China accounted for 4.8% of the global viral vector and plasmid dna manufacturing market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China viral vector and plasmid dna manufacturing market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,176.0 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viral Vector And Plasmid DNA Manufacturing Market Scope
Viral Vector And Plasmid DNA Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Batavia Biosciences | View profile | 101-250 | Leiden, Zuid-Holland, The Netherlands, Europe | http://www.bataviabiosciences.com/ |
| Regenxbio Inc | View profile | 344 | 9804 Medical Center Drive, Rockville, MD, United States, 20850 | https://www.regenxbio.com |
| Biomarin Pharmaceutical Inc | View profile | 3401 | 770 Lindaro Street, San Rafael, CA, United States, 94901 | https://www.biomarin.com |
| BioNTech SE ADR | View profile | 6133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | https://www.biontech.de |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Miltenyi Biotec | View profile | 1001-5000 | Bergisch Gladbach, Nordrhein-Westfalen, Germany, Europe | http://www.miltenyibiotec.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Revvity Inc | View profile | 11500 | 940 Winter Street, Waltham, MA, United States, 02451 | https://www.revvity.com |
| Takara Bio Inc | View profile | 1793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | http://www.takara-bio.co.jp |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
China viral vector and plasmid dna manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to viral vector and plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Lentivirus was the largest segment with a revenue share of 20.97% in 2025. Horizon Databook has segmented the China viral vector and plasmid dna manufacturing market based on adeno-associated virus (aav), lentivirus, adenovirus, retrovirus, plasmids covering the revenue growth of each sub-segment from 2021 to 2033.
China viral vectors and plasmid DNA manufacturing market is expected to grow at a lucrative rate owing to advancements in the regulatory framework for cell-based research activities in the country.
Furthermore, several biopharmaceutical companies are shifting their focus toward these advanced therapies with increasing investment in the field of cell & gene therapy.
For instance, in April 2022, Vector Builder announced an investment of USD 500 million to build a new cell research and gene therapy research & manufacturing facility in Guangzhou, China.
Reasons to subscribe to China viral vector and plasmid dna manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China viral vector and plasmid dna manufacturing market databook
-
Our clientele includes a mix of viral vector and plasmid dna manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China viral vector and plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into China viral vector and plasmid dna manufacturing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
China Vector Type - Viral Vector And Plasmid Dna Manufacturing Market size, 2025 - 2033 (US$M)
China Viral Vector And Plasmid DNA Manufacturing Market Outlook Share, 2025 & 2033 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
